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ABSTRACT
BACKGROUND: Several antioxidants have been found to have conflicting results
in attenuating myocardial reperfusion injury. These studies were done primarily in
experimental protocols that did not approximate clinical situations.
OBJECTIVE: The aim of this study was to test the efficacy of 3 different antioxi-
dants (ascorbic acid [AA}, desferrioxamine, and N-acetylcysteine [NAC}) adminis-
tered IV alone and in combination in a closed-chest pig model.
METHODS: Farm-raised domestic male pigs (aged 3-5 months, weight of 30-
35 kg) were assigned to 1 of 5 groups to receive treatment as follows: group A, AA
100 mg/kg; group B, desferrioxamine 60 mg/kg; group C, a loading dose of NAC
100 mg/kg for 20 minutes and a 20-mg/kg maintenance dose; group D, all 3 drugs
in combination; and group E, normal saline (control group). The infusion of all drugs was
started 15 minutes before and completed 5 minutes after reperfusion, except for the
administration ofNAC, which was terminated 60 minutes postreperfusion. Myocardial
ischemia (45 minutes) and reperfusion (210 minutes) were achieved percutaneously by
circumflex artery balloon occlusion. Ejection fraction, left ventricular end-diastolic
pressure (LVEDP), flow in the infarcted artery, and all ventricular arrhythmias were
recorded. Oxidative stress was estimated by serial measurements of thiobarbituric acid
reactive substance (TBARS) concentration in coronary sinus blood. Infarct size was
assessed as a percentage of the area at risk (I/R ratio) using the tetrazolium red stain-
ing method.
RESULTS: The 25 pigs were divided into 5 groups of 5 pigs each. No significant
between-group differences were found in I/R ratio or in oxidative stress (as measured
by TBARS concentration). Group C developed significantly more ventricular ar-
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rhythmias than the control group (80% vs 0%, P = 0.02). No other differences
among groups were found. LVEDP was significantly elevated in all treatment
groups (mean LVEDP difference [SD} for group A, 6.0 [1.6} mm Hg; group B,
17.6 [1.9} mm Hg; group C, 3.6 [1.7} mm Hg; group D, 6.8 [3.2} and group E, 5.4
[3.4} mm Hg). LVEDP elevation was found to be significantly higher in group B
compared with all the other groups (all, P < 0.001). No significant between-group
differences were found in the other parameters measured.
CONCLUSION: In this experimental pig model, the antioxidants AA, desferriox-
amine, and NAC administered alone or in combination did not reduce the deleterious
effects of reperfusion injury and specifically the extent of myocardial necrosis. (Curr
Ther Res Clin Exp. 2008;69:423-439) © 2008 Excerpta Medica Inc.
KEY WORDS: myocardial infarction, reperfusion injury, antioxidants, combination.
INTRODUCTION
Myocardial reperfusion injury is a well-documented phenomenon that partially offsets
the benefits of successful pharmaceutical or mechanical restoration of coronary blood
flow in acute myocardial infarction. I This phenomenon causes a spectrum of clinical
events, including arrhythmogenesis, temporary or permanent loss of contractile func-
tion (myocardial stunning or necrosis), and endothelial or microvascular dysfunction
(no-reflow phenomenon).2,3
Oxidative stress through production of reactive oxygen species (ROS) is considered
an important mediator in the pathophysiology of this phenomenon.4- 7 To attenuate
myocardial reperfusion injury, researchers have tested numerous antioxidants either
alone or in combination. Although many of these antioxidants have been found to be
effective in experimental models, they have not been found to be effective in clinical
trials. 8 One reason for this contradiction is that it is difficult to approximate clinical
myocardial ischemialreperfusion conditions in experimental protocols.9,lo Another
reason is the complexity of this paradoxical phenomenon. Reperfusion injury involves
many different mechanisms that cannot be suspended by a single antioxidant; a com-
bination of antioxidants is needed. ll Therefore, researchers have proposed studying a
combination of antioxidants (antioxidant cocktails) in experimental models that re-
semble the clinical setting of myocardial ischemia/reperfusion.8,12-14
We hypothesized that administration of a combination of antioxidants that act at
different sites in the pathophysiologic cascade of reperfusion injury may be more effec-
tive than administering these agents alone. We selected 3 well-known antioxidants-
ascorbic acid (AA), desferrioxamine, and N-acetylcysteine (NAC}--that act at 3 dif-
ferent sites in the reperfusion cascade.
AA is a potent water-soluble antioxidant present inside the cells of various body
fluids, tissues, and plasma. 15 It acts as a direct scavenger of the ROS produced im-
mediately after myocardial perfusion. 16 The antioxidant properties of desferrioxamine
are attributed to its ability to chelate free-ferric ions released from damaged myocar-
dial tissue.!7 In this way, desferrioxamine blocks Fenton reactions and limits the
production of potent radicals, thereby reducing the myocardial damage caused indi-
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recdy by the conversion of relatively noncytotoxic radicals to highly toxic ones. 18- 22
NAC, a thiol group donor, increases endogenous myocardial cell antioxidant defense
by restoring intracellular glutathione storesJ,23,24
To determine whether the combination of these drugs is effective in preventing
myocardial reperfusion injury by reducing oxidative stress, the 3 antioxidants were
administered IV alone and in combination in a closed-chest pig experimental preclini-
cal model. Myocardial reperfusion injury was assessed primarily by the extent of in-
duced myocardial necrosis. Secondary end points were the indices of left ventricular
function and the incidence of arrhythmias in the reperfusion period. The effect of
antioxidants on markers of oxidative stress was also assessed.
MATERIALS AND METHODS
This study was performed in the Animal and Experimental Laboratory at loannina
University Hospital, loannina, Greece. The study was conducted in compliance with the
Guide for the Care and Use of Laboratory Animals prepared by the National Academy
of Sciences25 and approved by the Ethics Committee of loannina University Hospital.
ANIMAL PREPARATION
Twenty-eight young (aged 3-5 months) male, farm-raised, domestic pigs (weight,
30-35 kg) were anesthetized according to the following protocol. All pigs were raised
in a modern indoor farm affiliated with the University of loannina, specifically de-
signed for small-group pig housing with stable conditions of ventilation, tempera-
ture, and feeding. Pigs are raised until the desirable age and weight, specifically for
the experiments in our institution. The animals were premedicated with azaperone
4 mg/kg and ketamine 5 mg/kg 1M. Anesthesia was induced with thiopental 7 mg/kg
IV. After endotracheal intubation, mechanical ventilation was started and anesthesia
was maintained with sevoflurane 1% and periodic administration of fentanyl and
vecuronium. The animals were ventilated with a mixture of air and oxygen to main-
tain their arterial blood gas values in the physiologic range. Electrocardiogram (ECG),
vital signs, and arterial blood gases were monitored throughout the procedure.
The right internal jugular vein was surgically exposed and a 7 French (Fr) sheath
(Glidesheath, Terumo Corp., Tokyo, Japan) was introduced. Under fluoroscopic guidance
a 7 Fr multipurpose catheter was placed in the coronary sinus for blood collection;
6 Fr sheaths were positioned in both femoral arteries using the Seldinger technique and
heparin 300 IU/kg IV was administered.26 Under fluoroscopic guidance a 6 Fr pig-tail
catheter was placed into the left ventricle to record left ventricular end-diastolic pressure
(LVEDP) and to perform left ventriculography to measure ejection fraction (EF) while the
left main stem of the left coronary artery was catheterized using a 6 Fr hockey-stick guid-
ing catheter.
EXPERIMENTAL PROTOCOL
After animal preparation and successful catheterization of the main stem of the left
coronary artery, the animals were assigned to 1 of 4 treatment groups (group A, AA
100 mg/kg; group B, desferrioxamine 60 mg/kg; group C, NAC 100 mg/kg for
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20 minutes + a 20-mg/kg maintenance dose; group D, AA 100 mg/kg + desferriox-
amine 60 mg/kg + NAC 100 mg/kg for 20 minutes + a 20-mg/kg maintenance dose)
or to group E (control group), normal saline. The assignment of animals was based on
the chronological order of the consecutive experiments (eg, experiment 1, group A;
experiment 2, group B; following accordingly from groups A-E in repeat cycles); this
process, although incomplete, allowed for randomization of the study experiments.
Furthermore, all studied parameters were measured by independent observers blinded
to the assigned treatment. Each animal received the allocated intravenous treatment
diluted in normal saline to a total volume of 100 mL. The infusion of all substances
started 15 minutes before reperfusion and was completed 5 minutes after, except for
the administration of NAC which was terminated 60 minutes after reperfusion. The
mode ofNAC administration was based on previously published studies. 27 ,28
Coronary artery occlusion was accomplished percutaneously by inflating an angio-
plasty balloon catheter (2.5 X 20 mm) positioned in the middle circumflex artery
(LCX) over a 0.014-in guidewire. Vessel occlusion was confirmed by the lack of con-
trast medium penetration beyond the position of the balloon and by the appearance
of ST-segment elevation in the limb ECG leads. The balloon remained inflated for
45 minutes and was subsequently deflated to restore blood flow. Figure 1 shows a
schematic representation of the experimental protocol.
MONITORING OF VENTRICULAR ARRHYTHMIA AND ASSESSMENT OF LVEDP,
LEFT VENTRICULAR SYSTOLIC FUNCTION, AND CORONARY BLOOD FLOW
During the first 60 minutes of reperfusion, all animals were monitored for ven-
tricular arrhythmias (ventricular fibrillation, sustained ventricular tachycardia [SVT},
nonsustained ventricular tachycardia [NSVT}, and idioventricular rhythm). SVT that
required cardioversion was considered to be as important as ventricular fibrillation
(VF) and was recorded as such. LVEDP measurements were obtained prior to ischemia
and 60 minutes after reperfusion. At the same time points, both coronary angiography
and left ventriculography at the 30° right anterior oblique projection were performed.
Flow in the LCX was graded according to the Thrombolysis In Myocardial Infarction
(TIMI) classification as follows 29: TIMI 0 = total occlusion of the infarct-related ar-
tery; TIMI 1 = slow and incomplete opacification of the infarct-related artery after
the site of occlusion; TIMI 2 = slow but complete opacification of the infarct-related
artery; TIMI 3 = normal opacification. Using left ventriculography, EF was measured
offline by an independent investigator who was blinded to the administered treatment
(CAAS, Pie Medical, Maastrich, The Netherlands).
ASSESSMENT OF THE ISCHEMIC AREA AT RISK AND THE PROPORTION OF THE
INFARCTED MYOCARDIAL ZONE
Two hundred ten minutes postreperfusion the angioplasty balloon was repositioned
in the LCX using the side branches as landmarks and was reinflated to occlude the
vessel. Then, 2 mL/kg of Evans blue 2% solution was infused into the beating left
ventricle through the pig-tail catheter to delineate the area at risk (ie, the area sub-
jected to ischemia and subsequent reperfusion). Three minutes after the administra-
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Figure 1. Schematic representation of the experimental protocol. NAC = N-acetylcysteine; LVEDP = left ventricular end-diastolic
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acid reactive substance.
!'z
z
;0:
l>
Ul
11\
-I
l>
I""
CURRENT THERAPEUTIC RESEARCH
tion of Evans blue solution, the animal was sacrificed by rapid intracardiac injection
of a potassium chloride solution.
The heart was excised rapidly (within 3 minutes), the atria and the right ventricle
were discarded, and the left ventricle was cut from the base to the apex in parallel
slices 0.5 cm in thickness. Members of an experienced team of the Forensic Depart-
ment of our institution who were blinded to the treatment of each animal were re-
sponsible for preparing and staining the excised heart and for assessing the infarcted
area and the area at risk of the myocardium studied. The area at risk of each slice was
the area that was not stained blue. In each slice, the borders of the area at risk were
demarcated with India ink to maintain their visibility after incubation of the slices in
triphenyl tetrazolium chloride (TTC). The slices were then incubated in a 1% TTC
solution for 30 minutes at 37°C in a dark room. At the end of this process, 2 areas
could be identified within the area at risk (the Evans blue unstained area): (1) the
TTC-stained area, with a characteristic brick-red color, was the ischemic but viable
myocardium; and (2) the TTC-unstained area represented the nonviable (infarcted)
tissue. 30 The slices were photographed with a digital camera. The areas at risk and the
infarcted areas were measured using a computer program (UTHSCSA-ImageTool,
version 3.00, San Antonio, Texas). These areas were multiplied by the thickness of
the slice (0.5 cm), and the volumes of risk and infarction were calculated for each
slice. By summing these volumes, the total volume of risk and infarction were esti-
mated for the whole left ventricle. The IIR ratio was defined as the proportion of the
myocardium at risk (R) that was necrotic (infarcted) (I). The total left ventricle (LV)
area and the proportion of the myocardium at risk to the total LV area were also
measured.
EVALUATION OF OXIDATIVE STRESS
Oxidative stress was assessed using thiobarbituric acid reactive substances
(TBARS), an indicator of lipid peroxidation widely used as an indirect method of es-
timating oxidative stress in clinical and experimental studies,31-33 Measurement of
TBARS concentration was made in blood samples collected from the coronary sinus.
The first blood sample (control sample taken at time point °minutes) was taken just
after the catheter was inserted in the coronary sinus and before ischemia was initiated.
After reperfusion, blood samples were collected at 2, 30, 60, 120, and ISO minutes.
Blood was carefully aspirated from the coronary sinus into solid glass reagent tubes
containing ethylenediaminetetraacetic acid (Greiner Bio-One GmbH, Kremsmiinster,
Austria). All samples were immediately placed in ice and centrifuged at 5000 rpm at
4°C for 15 minutes to separate setum. The setum was then collected with a small
pipette, placed in 1.5-mL Eppendorf tubes, and stored at -SO°C until processing.
TBARS concentrations were measured using the fluorometric method previously de-
scribed in detail by Wasowicz et al,34
STATISTICAL ANALYSIS
All continuous variables are expressed as mean (SD) unless mean (SEM) is indi-
cated. Statistical significance among groups was evaluated using I-way analysis of
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variance (ANOVA) followed by the Bonferroni multiple-comparison test (for post hoc
comparisons). Repeated-measures ANOVA ofTBARS concentration within the treat-
ment groups was performed using general linear model repeated measures to attempt
to reduce repeated sampling error (a bias inherent with this type of comparison).35
AVC was used to evaluate data abour the time course of the release of TBARS after
reperfusion. Categoric variables of separate groups were compared using the Fisher
exact test. P s:; 0.05 was considered statistically significant. Statistical analysis was
performed using SPSS version 13.0 (SPSS Inc., Chicago, Illinois). The number of
animals studied in each group was based on similar complex experimental studies in
the literature lO,36 and on the expectation of a large difference to be achieved with the
pharmacological intervention (eg, the administration of antioxidants compared
with the control infusion would reduce the I/R ratio by > 50% or would abolish
arrhythmias).
RESULTS
Of the 28 pigs included in the study, 3 died prior to group assignment and initia-
tion of ischemia (2 due to fatal bradycardia at the time of intubation and initiation
of anesthesia and 1 due to left main artery dissection during catheter engagement).
The surviving 25 animals were assigned to the 5 study groups (n = 5 per group).
Heart rate and mean aortic pressure were similar in all groups throughout the
experiment.
I/R RATIO
At the end of the procedure, the I/R ratio was as follows: group A, 0.42 (0.05);
group B, 0.40 (0.07); group C, 0.33 (0.07); group D, 0.39 (0.08); and group E,
0.29 (0.04) (Figure 2). Comparison using ANOVA found a significant difference in
I/R ratio among the groups (P = 0.03). Post hoc analysis revealed a trend towards a
larger I/R ratio in the group that received ascorbic acid (group A) in comparison to
the control group (P = 0.06). No significant statistical differences were found between
the other treatment groups. The proportion of the area of myocardial risk to the total
LV area did not differ among the treatment groups.
ARRHYTHMIAS
In group E no animal developed VF/SVT, while in groups A, B, C, and D, 1,2,4,
and 1 animals, respectively, developed VF/SVT after reperfusion. There was a signifi-
cant difference in the incidence of VF/SVT between groups E and C (P = 0.02). Two
animals had multiple episodes ofVF/SVT: 1 in group A had 5 consecutive episodes of
VF/SVT and 1 in group D had 2 episodes of VE In all of these episodes the animals
were successfully defibrillated. Most of the VF/SVT episodes (6 t86%}) occurred dur-
ing the first 10 minutes after reperfusion.
The mean (SD) numbers of NSVT and idioventricular rhythm episodes were as
follows: group A, 11.4 (8.9); group B, 14.8 (5.8); group C, 11.0 (3.8); group D,
14.4 (9.9); and group E, 9.8 (6.9). There were no significant between-group
differences.
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Figure 2. Mean (SEM) proportion of the at-risk myocardium that is infarcted (VR ratio)
by treatment group. NAC =N-acetylcysteine.
LEFT VENTRICULAR FUNCTION
LVEDP was significantly elevated 60 minutes after reperfusion in all treatment
groups compared with baseline (all, P < 0.01) (Figure 3). The mean (SD) differ-
ences were as follows: group A, 6.0 0.6) mm Hg; group B, 17.6 (1.9) mm Hg;
group C, 3.6 (1.7) mm Hg; group D, 6.8 (3.2) mm Hg; and group E, 5.4 (3.4) mm Hg.
Using ANOVA, LVEDP elevation was found to be significantly higher in group B
compared to all the other groups (all, P < 0.001). No significant differences were
found between the other groups.
One hour after reperfusion, EF was found to be significantly reduced compared
with baseline in all of the groups (all, P < 0.001) (Figure 4). No significant between-
group differences were found in changes in EF after reperfusion.
CORONARY FLOW
Optimal coronary blood flow (TIMI score, 3) after reperfusion was found in 3 ani-
mals in group C; 1 each in groups A, D, and E; and none in group B. No significant
difference was found among group comparison.
OXIDATIVE STRESS
TBARS concentrations were assessed at different time points throughout the rep-
erfusion period (Figure 5). No significant between-group differences were found in
baseline TBARS concentrations. Compared with baseline (0 minutes), TBARS concen-
trations were significantly elevated at 30 minutes in group E and at 120 minutes in
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Figure 3. Mean (SEM) left ventricular end diastolic pressure (LVEDP) at baseline and
60 minutes after reperfusion. *p < 0.05 baseline versus 60 minutes after rep-
erfusion; tp < 0.001 desferrioxamine group versus all other groups. NAC =
N-acetylcysteine.
group C (both, P = 0.02). In group B, TBARS concentrations decreased significantly
at 2 minutes and 120 minutes (both, P = 0.002) after reperfusion. No significant
change in TBARS concentrations was noted in group D.
ANOVA of AUC for all groups and for the total reperfusion period (180 minutes)
revealed no statistically significant between-group differences. Multiple comparisons
between TBARS concentrations at each time point found significantly higher concen-
trations in group A compared with group B at 120 minutes after reperfusion (P =
0.05) (Figure 5).
DISCUSSION
This study examined the effects of AA, desferrioxamine, and NAC administered in-
travenously alone and in combination on reperfusion injuty using an experimental
closed-chest pig model of a 45-minute ischemia period followed by 210 minutes of
reperfusion. No significant effect on reperfusion injuty was found with any of the
treatments.
ASCORBIC ACID
Experimental studies of the antioxidant effects of AA after reperfusion have re-
ported contradictory findings. Some studies reported a protective effect when AA was
administered alone or in combination with other agents in isolated cardiomyocytes
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Figure 4. Mean (SEM) ejection fraction (EF) measured off-line at baseline and 60 minutes
postrepertusion. No significant between-group differences were found. NAC =
N-acetylcysteine. *All, P < 0.001 versus baseline.
and in vivo experimental models,37,38 while others found no such protective effect
from reperfusion injury, even when the drug was administered prior to coronary
occlusion. 13,39
In our study, the infarct size increased numerically, though not significantly, in ani-
mals receiving AA alone compared with the control group. In the same animals, an
increase was also observed in oxidative stress measured by TBARS concentration.
These findings are in accordance with the results of previous in vitro studies that re-
ported possible prooxidative activity of AA that was attributed either to ascorbate
auto-oxidation or to a significant reduction of intracellular reducing agents, such as
glutathione.40,41 Ascorbate auto-oxidation is a well-described phenomenon occurring
especially in the presence of iron or copper ions released in myocardial tissue as free
catalytic metals. 21 ,40 The significant depletion of endogenous antioxidants, particu-
larly those of glutathione, prohibits the intracellular reduction of dehydroascorbate
(the major transport form of AA) to AA, thereby ameliorating its protective effects or
even demonstrating a prooxidative action. 41
DESFERRIOXAMINE
Desferrioxamine has been widely studied as a free-radical scavenger. Previous studies
have reported beneficial effects, mostly when desferrioxamine was administered before
the onset of ischemia. 19,42 Subsequent clinical trials found desferrioxamine had a protec-
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Figure 5. Mean (SEM) thiobarbituric acid reactive substance (TBARS) concentrations at
different time points throughout the reperfusion period. *P =0.002 desferriox-
amine group versus baseline; tp = 0.02 control group versus baseline; 1'p = 0.02
NAC group versus baseline; §p = 0.05 ascorbic acid group versus desferriox-
amine group. NAC = N-acetylcysteine.
tive role, particularly in patients undergoing coronary artery bypass graft (CABG) sur-
gery.32,43 However, desferrioxamine can only be administered early in cases of elective
reperfusion, such as CABG surgery, but not in acute myocardial infarction.
Our model was designed to resemble clinical scenarios of myocardial infarction;
therefore, the drugs had to be administered after the initiation of ischemia and prior
to reperfusion. Desferrioxamine was not found to provide sufficient protection against
reperfusion under these circumstances. In addition, a significant increase in LVEDP
was found 1 hour after reperfusion, indicating significant left ventricular dysfunction
in these animals, possibly associated with a toxic effect of desferrioxamine on the
myocardium. This phenomenon has been mainly attributed to an oxidative action of
desferrioxamine.44 Borg and Schaich proposed a dose-dependent biphasic antioxidant/
prooxidant behavior of desferrioxamine: at low doses it responds as a chelating agent,
while at high doses it paradoxically amplifies oxidative damage. 44 In our study, how-
ever, oxidative stress (measured by TBARS concentration) was not found to increase
in animals receiving desferrioxamine; on the contrary, a significant decrease in TBARS
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concentrations was found, particularly 120 minutes after teperfusion. This observa-
tion provides evidence that oxidative toxicity may not be the reason for desferriox-
amine failure; other mechanisms may be implicated in the worsening LV function
observed in the current study. Because of its relatively low lipophilic characteristics,
desferrioxamine might not sufficiently penetrate cellular and mitochondrial mem-
branes. Therefore, it cannot protect sensitive intracellular homeostasis mechanisms,
leading to cardiac myocyte dysfunction and subsequent impaired LV function. 45
N-ACETYLCYSTEINE
Administration of NAC early in the ischemic period can attenuate both postreper-
fusion myocardial necrosis and Sl unning. 24,46 However, if it is administered late (after
ischemia initiation or on reperfusion), NAC was not found to be protective27 ,47; our
results confirm this finding.
Animals treated with NAC had the same incidence of NSVT and idioventricular
rhythm as the other groups, bur they had a relatively higher incidence of VF/SVT
(proarrhythmic effect), indicating that late intravenous administration ofNAC during
ischemia did not protect against reperfusion ventricular arrhythmias. Previous studies
found a protective effect of NAC on reperfusion arrhythmias; however, this was
achieved only when NAC was infused from the beginning of ischemia until late in the
reperfusion period.9,24,48 Although the exact reason for the proarrhythmic effect of
NAC in our pig model cannot be fully clarified, the increased oxidative stress ob-
served as increased TBARS concentration in the NAC group could be a possible cause.
This speculation is supported by the finding that thiol-containing compounds, such
as NAC, are capable of forming species with potentially toxic effects (eg, thiol, peroxy
sulphenyl radicals) that can limit the expected benefits of the antioxidant properties
ofNAC.49
COMBINATION OF DRUGS
In the presence of conflicting data regarding the protective role of antioxidants,
researchers have suggested that antioxidant combinations might be more effective
than monotherapy in preventing the deleterious effects of reperfusion injury, possibly
through a synergic effect.8,12,13 Previous experiments investigating the action of dif-
ferent drug combinations had contradictory results. 13 ,50 Our study found that the
combination of AA, desferrioxamine, and NAC administered via IV was not effective
in protecting against reperfusion injury.
The elevated TBARS concentration in the control group confirmed oxidative stress
as one of the important mediators in the pathophysiology of reperfusion injury. How-
ever, although the different antioxidant agents decreased the amount of oxidative
stress, they did not have a protective effect on reperfusion injury. The route of admin-
istration may be an important factor in Out findings. Previous studies in pigs found
a protective effect of different agents only with retrograde administration (ie, via car-
diac veins) and not when they were infused via IV. 10,36 However, IV administration
remains the most common route for infusing various drugs duting pharmaceutical
(thrombolysis) or mechanical (primary coronary angioplasty) reperfusion. Intracoronary
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or retrograde administration of these drugs can be done in a sting of primary coro-
nary angioplasty but not in the case of pharmaceutical IV thrombolysis. In addition,
such administration requires special complex catheterization techniques that will in-
crease the time to perfusion, thereby ameliorating the potential benefit.
Other important factors in this study were the timing and the period of adminis-
tration of the antioxidant agents. All of these drugs were found to have positive results
in studies in which they were administered before the initiation of ischemia.46,51,52
However, in clinical practice it is not feasible to administer these drugs before the
onset of symptoms of myocardial infarction. In our experimental protocol, all drugs
were administered just before reperfusion, as would have been done in the case of a
patient presenting with acute myocardial infarction requiring thrombolysis or pri-
mary percutaneous intervention. In the present study, we approximated the drug
doses that have been found to be beneficial in experimental and clinical trials. 24,28,52-57
It remains unknown whether the administration of the combination of these drugs in
different doses, for different time periods, and via different routes would have resulted
in more or less favorable outcomes.
LIMITATIONS
The most important limitation of the present study was the small number of animals
in each group. Only treatment effects ofgreat magnitude would be expected to be revealed
with such a small number of animals, and these were not observed in our study.
Although the present experimental study was designed to resemble the actual clinical
conditions of myocardial ischemia/reperfusion, all such experimental models have im-
portant differences compared with the setting of myocardial infarction in humans.
TBARS concentration in coronary sinus blood samples, which has been widely used
in clinical and experimental studies as an indirect marker of oxidative stress, was used
for that purpose in this study. However, direct measurement of ROS using electron
spin resonance spectroscopy or study of oxidative stress markers in myocardial tissue
might result in different findings.
Finally, all animals were euthanized by intracardiac injection of potassium, a widely
acceptable method of euthanasia in fully anesthetized animals that causes immediate
asystole. 58 Therefore, an impact of potassium on the ischemic or necrotic area of the
myocardium was not anticipated and has not been studied in detail. Furthermore, be-
cause this procedure was used in all 5 groups, it should not have affected the between-
group comparisons.
As reperfusion injury remains an unresolved clinical problem, studies of new drugs
that achieve high concentrations in the myocardial zone and studies of alternate routes
of administration are needed.
CONCLUSION
We found that in this experimental closed-chest pig model mimicking clinical sce-
narios of myocardial infarction and reperfusion that AA, desferrioxamine, and NAC
alone or in combination did not provide significant protection from reperfusion oxida-
tive damage.
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